Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasis
03/24/2014
New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the study's primary endpoint.